Cargando…

Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity

Induction of selective, autoantigen-specific tolerance is the “holy grail” for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: von Herrath, Matthias G., Nepom, Gerald T.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213225/
https://www.ncbi.nlm.nih.gov/pubmed/16275758
http://dx.doi.org/10.1084/jem.20051224
_version_ 1782148851718684672
author von Herrath, Matthias G.
Nepom, Gerald T.
author_facet von Herrath, Matthias G.
Nepom, Gerald T.
author_sort von Herrath, Matthias G.
collection PubMed
description Induction of selective, autoantigen-specific tolerance is the “holy grail” for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12–16, 2005, in Boston, MA, a Kirin-sponsored “Ideashop” was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies.
format Text
id pubmed-2213225
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22132252008-03-11 Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity von Herrath, Matthias G. Nepom, Gerald T. J Exp Med Meeting Review Induction of selective, autoantigen-specific tolerance is the “holy grail” for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12–16, 2005, in Boston, MA, a Kirin-sponsored “Ideashop” was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies. The Rockefeller University Press 2005-11-07 /pmc/articles/PMC2213225/ /pubmed/16275758 http://dx.doi.org/10.1084/jem.20051224 Text en Copyright © 2005, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Meeting Review
von Herrath, Matthias G.
Nepom, Gerald T.
Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
title Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
title_full Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
title_fullStr Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
title_full_unstemmed Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
title_short Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
title_sort lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
topic Meeting Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213225/
https://www.ncbi.nlm.nih.gov/pubmed/16275758
http://dx.doi.org/10.1084/jem.20051224
work_keys_str_mv AT vonherrathmatthiasg lostintranslationbarrierstoimplementingclinicalimmunotherapeuticsforautoimmunity
AT nepomgeraldt lostintranslationbarrierstoimplementingclinicalimmunotherapeuticsforautoimmunity